Robbins Umeda LLP Announces an Investigation of the Acquisition of Chattem, Inc. by Sanofi-aventis

Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of Chattem, Inc. ("Chattem") (NASDQ:CHTT) in connection with their actions in causing Chattem to enter into a definitive merger agreement with Sanofi-aventis ("Sanofi"). Under the terms of the agreement, Chattem shareholders will receive $93.50 in cash for each share of Chattem they own. The tender offer will commence in January 2010, and the companies expect the transaction to close in the first quarter of 2010.

Chattem is approximately 130 years old and is a leading manufacturer and marketer of branded consumer healthcare products, toiletries, and dietary supplements across niche market segments in the United States. Chattem has regularly demonstrated its ability to sustain regular growth, both in terms of sales and profit, through the development of its own brands and the successful integration of acquired products. Chattem's well known brands include Gold Bond®, Icy Hot®, ACT®, Cortizone-10®, Selsun Blue®, and Unisom®.

Robbins Umeda LLP's investigation concerns whether Chattem's Board of Directors' acceptance and recommendation of the offer was fair and designed to secure the best possible price for all Chattem shareholders.

If you are a shareholder of Chattem and would like more information about your rights as a shareholder, please contact attorney Lauren Levi at 800-350-6003 or by e-mail at llevi@robbinsumeda.com.

Robbins Umeda LLP is a California-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please go to http://www.robbinsumeda.com.

Chattem, Inc. (MM) (NASDAQ:CHTT)
過去株価チャート
から 12 2024 まで 1 2025